Turkey Cancer Drugs Clinical Trials Market Oulttok
More Than 180 Cancer Drugs Are In Clinical Trials Says Kuick Research In Recent Publish Report On Cancer Drugs Clinical Trials in Turkey
Delhi, July 30, 2024 (GLOBE NEWSWIRE) — Turkey Cancer Drugs Clinical Trials Insight 2024 Report Offering:
-
Turkey Clinical Trials Market Opportunity 2024 & 2030 (In US$ Million)
-
Clinical Trials Regulatory Framework In Turkey
-
Total Number of Cancer Drugs In Clinical Trials In Turkey
-
Total Number Of Cancer Drugs Approved In Turkey
-
300 Pages Clinical Trials Insight on All Cancer Drugs In Clinical Trials By Company, Indication & Phase
-
50 Pages Clinical Insight On All Cancer Drugs Approved in Market By Company & Indication
-
Insight On 18 Pharmaceutical Companies & 5 CRO
Download Report: /report-turkey-cancer-drugs-clinical-trials
Turkey has emerged as a significant player in the global clinical trial landscape, offering a unique blend of advantages that make it an increasingly attractive destination for pharmaceutical companies and contract research organizations. Apropos to our data, more than 240 clinical trial studies are ongoing in the country; representing novel opportunism in the looming years. Interalia, the Turkish clinical trial market has been expanding rapidly in recent years, driven by a combination of factors that set it apart from both its regional neighbors and Western countries.
One of the primary advantages of conducting clinical trials in Turkey is its large and diverse populace of over 80 million people as of 2024. Researchers can access a diverse range of patient groups, such as individuals without prior treatment and those with uncommon diseases, thanks to this demographic profile. Turkey’s historical location at the meeting point of Europe and Asia has contributed to its genetic diversity. This diversity makes it a valuable study partner for a range of genetic backgrounds and may yield more broadly applicable research findings.
Compared to Western countries, Turkey offers significant cost advantages in conducting clinical trials. While maintaining high-quality standards, the overall expenses associated with clinical research in Turkey are generally lower than in North America or Western Europe. This cost-effectiveness extends to areas such as investigator fees, site costs, and patient recruitment, allowing sponsors to optimize their research budgets without compromising on quality.
Together with, regulatory processes in Turkey have also seen significant improvements, contributing to the expansion of its clinical trial market. The Turkish Medicines and Medical Devices Agency (TITCK) has made concerted efforts to align its procedures with international standards, including ICH-GCP guidelines and EU regulations. While regulatory timelines in Turkey may still be longer than in some Western countries, they have been steadily improving, making the country more competitive in attracting global clinical studies. Furthermore, Turkey’s strategic geographical location offers another advantage over many Western countries. Its position bridging Europe and Asia allows for easy access to both regions, facilitating multi-center studies and enhancing logistical efficiency. This geographical advantage, combined with Turkey’s growing role as a regional hub for pharmaceutical companies, has contributed to the expansion of its clinical trial market.
Besides, the country’s growing pharmaceutical market and increasing government support for research and development activities have also played crucial roles in expanding Turkey’s clinical trial landscape. The Turkish government has been investing in initiatives to promote innovation in the life sciences sector, leading to the development of a skilled workforce and improved research capabilities. This support has created a more favorable environment for clinical research compared to some Western countries where research funding may be more constrained.
Furthermore, Turkey presents opportunities for conducting clinical trials in therapeutic areas that may be challenging to study in Western countries. For instance, the country has populations with certain diseases that are less common in the West, providing valuable research opportunities for companies developing treatments for these conditions. Despite these advantages, it’s important to note that Turkey’s clinical trial market still faces some challenges when compared to more established markets in Western countries. While regulatory processes have improved, sponsors may still encounter some bureaucratic hurdles, particularly for first-time operators in the country.
In conclusion, Turkey’s clinical trial market presents a compelling opportunity for pharmaceutical companies and researchers. As Turkey continues to invest in its research capabilities and streamline its regulatory processes, it is likely to further solidify its position as a key player in the global clinical trial landscape, providing an attractive alternative or complement to traditional research locations in the West.
CONTACT: Neeraj Chawla Kuick research Research Head +91-981410366 [email protected]
